scholarly journals Switching the basal insulin to insulin glargine 300 U/ ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety

2021 ◽  
Author(s):  
Jochen Seufert ◽  
Peter Wiesli ◽  
Andreas Fritsche ◽  
Helmut Anderten ◽  
Katrin Pegelow ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Therapy ◽  
Observational Trial

Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients (Pts) with Type 2 Diabetes (T2DM) on Basal Insulin Supported Oral Therapy (BOT)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1020-P ◽  
Author(s):  
JOCHEN SEUFERT ◽  
ANDREAS FRITSCHE ◽  
HELMUT ANDERTEN ◽  
KATRIN PEGELOW ◽  
STEFAN PSCHERER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Therapy ◽  
Nocturnal Hypoglycemia

Initiating Basal Insulin Supported Oral Therapy (BOT) with Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control in Patients (Pts) with Type 2 Diabetes (T2DM) without Increasing Hypoglycemia Risk

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1027-P
Author(s):  
MARTIN PFOHL ◽  
ANDREAS FRITSCHE ◽  
HELMUT ANDERTEN ◽  
KATRIN PEGELOW ◽  
STEFAN PSCHERER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Therapy

2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2192-PUB
Author(s):  
STEWART B. HARRIS ◽  
FRANK J. SNOEK ◽  
LUIGI MENEGHINI ◽  
FELIPE LAUAND ◽  
JUKKA WESTERBACKA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Randomized Controlled Trials ◽  
Real World ◽  
Basal Insulin ◽  
Treatment Satisfaction ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes

2018 ◽  
Vol 2018 ◽  
pp. 1-9
Author(s):  
Shuo Lin ◽  
Mu Chen ◽  
Wanling Chen ◽  
Keyi Lin ◽  
Panwei Mu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Insulin Infusion ◽  
Cell Function ◽  
Hypoglycemic Agents ◽  
Newly Diagnosed ◽  
Oral Hypoglycemic Agents

Aims. Basal insulin plus oral hypoglycemic agents (OHAs) has not been investigated for early intensive antihyperglycemic treatment in people with newly diagnosed type 2 diabetes. This study is aimed at comparing the short-term (over a period of 12 days) effects of basal insulin glargine plus OHAs and continuous subcutaneous insulin infusion (CSII) on glycemic control and beta-cell function in this setting. Methods. An open-label parallel-group study. Newly diagnosed hospitalized patients with type 2 diabetes and fasting plasma glucose (FPG) ≥11.1 mmol/L or glycated hemoglobin (HbA1c) ≥9% (75 mmol/mol) were randomized to CSII or insulin glargine in combination with metformin and gliclazide. The primary outcome measure was the mean amplitude of glycemic excursions (MAGE), and secondary endpoints included time to reach glycemic control target (FPG < 7 mmol/L and 2-hour postprandial plasma glucose < 10 mmol/L), markers of β-cell function, and hypoglycemia. Results. Subjects in the CSII (n=35) and basal insulin plus OHA (n=33) groups had a similar significant reduction from baseline to end of treatment in glycated albumin (−6.44 ± 3.23% and− 6.42 ± 3.56%, P=0.970). Groups A and B have comparable time to glycemic control (3.6 ± 1.2 days and 4.0 ± 1.4 days), MAGE (3.40 ± 1.40 mmol/L vs. 3.16 ± 1.38 mmol/L; p=0.484), and 24-hour mean blood glucose (7.49 ± 0.96 mmol/L vs. 7.02 ± 1.03 mmol/L). Changes in the C-peptide reactivity index, the secretory unit of islet in transplantation index, and insulin secretion-sensitivity index-2 indicated a greater β-cell function improvement with basal insulin plus OHAs versus CSII. Conclusions. Short-term insulin glargine plus OHAs may be an alternative to CSII for initial intensive therapy in people with newly diagnosed type 2 diabetes.

scholarly journals Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL ( EDITION 1 and EDITION 2 subgroup analysis)

2017 ◽  
Vol 20 (2) ◽  
pp. 448-452 ◽  
Author(s):  
Ronan Roussel ◽  
Michael C. d'Emden ◽  
Miles Fisher ◽  
F. Javier Ampudia‐Blasco ◽  
Peter Stella ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Insulin Glargine ◽  
Subgroup Analysis ◽  
Basal Insulin ◽  
Once Daily ◽  
Daily Insulin

scholarly journals Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 10 (3) ◽  
pp. 835-852 ◽  
Author(s):  
Wenchuan Zhou ◽  
Jinxin Tao ◽  
Xiaodong Zhou ◽  
Hongxia Chen
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Meta Analysis ◽  
Insulin Degludec ◽  
Long Acting

scholarly journals Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

2020 ◽  
Vol 22 (8) ◽  
pp. 1369-1377 ◽  
Author(s):  
Martin Haluzík ◽  
Alice Cheng ◽  
Dirk Müller‐Wieland ◽  
Jukka Westerbacka ◽  
Zsolt Bosnyak ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Insulin Glargine ◽  
Kidney Function ◽  
Basal Insulin
Sign in / Sign up

Export Citation Format

Share Document